Unichem Labs Goa facility gets VAI status from USFDA

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-09-11T11:15:15+05:30 | Updated On 11 Sept 2024 11:15 AM IST

Dr Reddys Bollaram Unit gets 7 USFDA Observations

Mumbai: Unichem Labs has announced that the US Food and Drug Administration (USFDA) has classified the inspection of Company’s Goa formulation facility situated at Pilerne, Bardez as Voluntary Action indicated (“VAI”).

Medical Dialogues team had earlier reported that the Company had received five observations from the USFDA for the inspection conducted from 8th July 2024 to 15th July 2024.

Headquartered in Mumbai, Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. The company was founded in 1944 by Padmabhushan Late Mr. Amrut V Mody. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.

unichem labsunichem labs newsUSFDAUSFDA inspection

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751